An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease — CMX

Ebola Virus Clinical Trial

Official title:
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02271347
Study type	Interventional
Source	Chimerix
Contact
Status	Withdrawn
Phase	Phase 2
Start date	October 2014
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02269423` - Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)	Phase 1
Completed	`NCT03719586` - Investigational Therapeutics for the Treatment of People With Ebola Virus Disease	Phase 2/Phase 3
Completed	`NCT04041570` - Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults	Phase 1
Completed	`NCT02344407` - Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)	Phase 2
Completed	`NCT02314923` - Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)	Phase 1